养胃颗粒联合铋剂四联疗法治疗Hp感染慢性非萎缩性胃炎脾胃气虚证临床研究  

Clinical Study on Yangwei Granules Combined with Bismuth Quadruple Therapy for Chronic Non-Atrophic Gastritis Caused by Hp Infection with Spleen-Stomach Qi Deficiency Syndrome

作　　者：韩芳 陈达伟 杨建巧 HAN Fang;CHEN Dawei;YANG Jianqiao(Dongxin Street Community Healthcare Center in Gongshu District of Hangzhou,Hangzhou Zhejiang 310014,China;Department of Gastroenterology,Zhejiang Qiushi Cardiovascular Hospital,Hangzhou Zhejiang 310023,China;Departmentof Internal Medicine,Hangzhou Gongshu District Hospital of Integrated Traditional Chinese and Western Medicine,Hangzhou Zhejiang 310011,China)

机构地区：[1]杭州市拱墅区东新街道社区卫生服务中心,浙江杭州310014 [2]浙江求是心血管病医院消化内科,浙江杭州310023 [3]杭州市拱墅区中西医结合医院内科,浙江杭州310011

出　　处：《新中医》2024年第17期39-43,共5页New Chinese Medicine

摘　　要：目的:观察养胃颗粒联合铋剂四联疗法治疗幽门螺杆菌(Hp)感染慢性非萎缩性胃炎脾胃气虚证的临床疗效。方法:选取106例Hp感染慢性非萎缩性胃炎患者,按随机数字表法分为对照组和观察组各53例。对照组予铋剂四联疗法,观察组在对照组基础上采取养胃颗粒治疗。2组连续治疗2周。比较2组临床疗效、胃肠道症状评分、Hp根除率、脾胃气虚证症状评分以及血清肿瘤坏死因子(TNF)-α、白细胞介素(IL)-2、IL-32水平。结果:2周疗程后,观察组总有效率为94.34%,高于对照组79.25%(P<0.05)。2周疗程结束后,观察组Hp根除率为92.45%,高于对照组75.47%(P<0.05)。治疗1周、2周后,2组胃肠道症状分级量表(GSRS)评分较治疗前降低(P<0.05);且观察组GSRS评分低于同时间点对照组(P<0.05)。治疗后,2组脾胃气虚证症状评分较治疗前降低(P<0.05);且观察组脾胃气虚证症状评分低于对照组(P<0.05)。治疗后,2组血清TNF-α、IL-32水平较治疗前降低,IL-2水平较治疗前升高(P<0.05);且观察组血清TNF-α、IL-32水平低于对照组,IL-2水平高于对照组(P<0.05)。结论:养胃颗粒联合铋剂四联疗法治疗Hp感染慢性非萎缩性胃炎脾胃气虚证的疗效明显,能改善患者胃肠症状与中医证候,提高Hp根除率,抑制炎症反应。Objective:To observe the clinical effect of Yangwei Granules combined with bismuth quadruple therapy for chronic non-atrophic gastritis caused by helicobacter pylori(Hp)infection with spleen-stomach qi deficiency syndrome.Methods:A total of 106 cases of patients with chronic non-atrophic gastritis caused by Hp infection were selected and divided into the control group and the observation group according to the random number table method,with 53 cases in each group.The control group was treated with bismuth quadruple therapy,and the observation group was additionally treated with Yangwei Granules based on the treatment of the control group.Both groups were continuously treated for two weeks.Clinical effects,gastrointestinal symptom scores,Hp eradication rates,symptom scores of the spleen and stomach qi deficiency syndrome,as well as levels of serum tumor necrosis factor(TNF)-α,interleukin(IL)-2,and IL-32 were compared between the two groups.Results:After two weeks of treatment courses,the total effective rate was 94.34%in the observation group,which was higher than that of 79.25%in the control group(P<0.05).After two weeks of treatment courses,the Hp eradication rate was 92.45%in the observation group,which was higher than that of 75.47%in the control group(P<0.05).After one and two weeks of treatment,the scores of the Gastrointestinal Symptom Rating Scale(GSRS)in the two groups were decreased when compared with those before treatment(P<0.05),and GSRS scores in the observation group were lower than those in the control group at the same time points(P<0.05).After treatment,symptom scores of the spleen-stomach qi deficiency syndrome in the two groups were decreased when compared with those before treatment(P<0.05),and symptom scores of the spleen-stomach qi deficiency syndrome in the observation group were lower than those in the control group(P<0.05).After treatment,levels of TNF-αand IL-32 in serum in the two groups were declined when compared with those before treatment,and IL-2 levels were increased(P<0.05);th

关 键 词：慢性非萎缩性胃炎 养胃颗粒 铋剂四联疗法 炎症因子 HP根除率 

分 类 号：R573.3[医药卫生—消化系统]